Expression of microRNA-218 and its Clinicopathological and Prognostic Significance in Human Glioma Cases

Cheng, Mao-Wei; Wang, Lingling; Hu, Guyu

doi:10.7314/apjcp.2015.16.5.1839

Cited by 15 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After further identification and screening individual study, 11 eligible publications underwent full-text review, and 1 article [22] was further excluded because data were unavailable. Finally, we included 10 eligible studies [12,13,23–30] in the final evidence synthesis.…”

Section: Resultsmentioning

confidence: 99%

“…Among the eligible studies, 10 articles [12,13,23–30] evaluated both OS and DFS/PFS/RFS, 6 articles [12,13,23,25,28,30] evaluated DFS/PFS/RFS. Seven studies [12,23,24,26–28,30] directly reported HRs and 95% CIs, three studies [13,25,29] reported survival curve (SC).…”

Section: Resultsmentioning

confidence: 99%

“…Seven studies [12,23,24,26–28,30] directly reported HRs and 95% CIs, three studies [13,25,29] reported survival curve (SC).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic significance of low microRNA-218 expression in patients with different types of cancer

et al. 2016

View full text Add to dashboard Cite

Background:Mounting evidence showed that microRNAs may be useful as prognostic biomarkers of cancer. Therefore, we summarize the predictive role of microRNA-218 (miR-218) for survival in patients with various cancers.Methods:We performed a systematic literature review and assessed the quality of included studies based on Meta-analysis of Observational Studies in Epidemiology group (MOOSE). Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the correlation between miR-218 expression and prognosis of different cancers.Results:We identified 10 studies for pooled analyses. For overall survival, a lower expression levels of miR-218 significantly predicted poorer survival, with the pooled HR of 2.61 (95% CI: 2.11–3.22, P < 0.001). For disease-free survival/progressive-free survival/recurrence-free survival (DFS/PFS/RFS), a lower expression level of miR-218 significantly predicted worse DFS/PFS/RFS in various carcinomas, with the pooled HR of 2.73 (95% CI: 2.08–3.58, P < 0.001). Similarly, subgroup analysis by detection method, ethnicity and cancer subtype analysis suggested that lower expression of miR-218 correlated with.Conclusion:Our data demonstrated that lower miR-218 expression is significantly associated with poorer overall survival (OS) and DFS/PFS/RFS and may be a novel prognostic biomarker in some cancer types.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of low microRNA-218 expression in patients with different types of cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In a number of other types of cancer, miR-218 has been suggested as a prognostic evaluation biomarker; in glioma, low expression of miR-218 was associated with a higher World Health Organization grade and lower Karnofsky scores (20). Furthermore, overexpression of miR-218 in human osteosarcoma Saos-2 cells repressed cell migration and invasion by targeting T-lymphoma invasion and metastasis-inducing protein 1, matrix metalloproteinase (MMP) 2 and MMP9 (21).…”

Section: Discussionmentioning

confidence: 99%

miR‑218 inhibits acute promyelocytic leukemia cell growth by targeting BMI‑1

et al. 2017

View full text Add to dashboard Cite

Abstract. Acute promyelocytic leukemia (APL) is a subtype of acute myelocytic leukemia. Previous studies have reported a number of functions and therapeutic roles of microRNAs (miRs) in APL, and have suggested that miR-218 acts as a tumor suppressor in a number of types of human cancer; however, its role in APL remains unclear. In the present study, the expression of miR-218 and its effects on the viability and proliferation of HL-60 cells was investigated. Reverse transcription-quantitative polymerase chain reaction analysis demonstrated that miR-218 was frequently downregulated in APL marrow tissues compared with normal marrow tissues. Overexpression of miR-218 significantly inhibited cell proliferation, arrested the cell cycle in the G 0 /G 1 phase and induced apoptosis. In addition, B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) mRNA expression was negatively associated with miR-218 expression; BMI-1 mRNA and protein expression were downregulated following transfection with miR-218 mimic. These results indicate that miR-218 functions as tumor suppressor in APL, and the miR-218/BMI-1 signaling axis may be a potential novel diagnostic marker and therapeutic target for the treatment of APL.

show abstract

“…Growing evidence has indicated a critical role of miRNAs in the tumorigenesis and development of different types of cancer including gliomas [6][7][8]. Among them, miR-218 has been reported to be highly downregulated in gliomas compared to normal brain tissues [9][10][11], and decreased expression of miR-218 is strongly associated with poor disease-free survival and overall survival in glioma patients [12].…”

mentioning

confidence: 99%

MiR-218 inhibits malignant phenotypes of glioma by targeting TNC/AKT/AP-1/TGFβ1 feedback signaling loop

Dang

Zhang

Tian

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Gliomas are the most common and malignant tumors in the brain of humans, and the prognosis of glioma patient is very poor. MicroRNAs (miRNAs) play critical roles in different types of cancer by regulating gene expression at the posttranscriptional levels. Although miR-218 has been reported to be downregulated in gliomas, its role in gliomas still remains largely unknown.Methods: MiR-218 expression in gliomas and normal brain tissues (control subjects) were analyzed using TCGA dataset. The biological roles of miR-218 in glioma cells were determined by a series of in vitro and in vivo studies. The dual-luciferase reporter system was performed to identify potential targets of miR-218. The regulatory effect of miR-218 on TNC/AKT/AP-1/TGFβ1 pathway was evaluated by dual-luciferase reporter system and western blot. Results:We demonstrated miR-218 was significantly downregulated in gliomas compared to control subjects, and exerted a potent tumor suppressor in glioma cells by inhibiting cell proliferation, colony formation, migration, invasion and tumorigenic potential in nude mice, as well as inducing cell cycle arrest and apoptosis.Mechanistically, miR-218 inhibited malignant phenotypes of glioma cells by binding to the 3' UTR of its target TNC and subsequently repressing its expression. As a result, it could reduce AKT phosphorylation and subsequently inhibit transcriptional activity of AP-1 by reducing JNK phosphorylation, downregulating the expression of TGFβ1, while TGFβ1 is able to, in turn, activate the TNC/AKT/AP-1 signaling axis. Conclusions:Our data uncover a previously unknown tumor suppressor role of miR-218 in glioma by blocking the TNC/AKT/AP-1/TGFβ1 positive feedback loop. BackgroundGliomas are the most common and malignant tumors in the brain of humans, which represent about 70% of all brain tumors [1]. The current standard of care for newly diagnosed gliomas patients includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy [2,3]. However, despite these treatment, overall survival rate of the patients suffering from glioma is among the lowest of all the main types of cancer and has not improved during recent decades [4].

show abstract

Expression of microRNA-218 and its Clinicopathological and Prognostic Significance in Human Glioma Cases

Cited by 15 publications

References 27 publications

Prognostic significance of low microRNA-218 expression in patients with different types of cancer

Prognostic significance of low microRNA-218 expression in patients with different types of cancer

miR‑218 inhibits acute promyelocytic leukemia cell growth by targeting BMI‑1

MiR-218 inhibits malignant phenotypes of glioma by targeting TNC/AKT/AP-1/TGFβ1 feedback signaling loop

Contact Info

Product

Resources

About